Related Experiment Video

Updated: May 14, 2026

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
04:23

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Carbohydrate-related inhibitors of dengue virus entry

Kazuya I P J Hidari1, Tomoko Abe, Takashi Suzuki

  • 1Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, and Global COE Program for Innovation in Human Health Sciences, 52-1 Yada, Suruga-ku, Shizuoka-shi, Shizuoka 422-8526, Japan. hidari@u-shizuoka-ken.ac.jp

Viruses
|February 8, 2013
PubMed

Insights

Carbohydrate-based compounds can block dengue virus (DENV) entry into human cells by interfering with its envelope protein. These findings offer potential for developing new dengue fever treatments.

Area of Science:

  • Virology
  • Molecular Biology
  • Biochemistry

Background:

  • Dengue virus (DENV) causes significant human illness, including fever and hemorrhagic disorders.
  • Virus entry into host cells, mediated by the viral envelope (E) protein and host receptors, is critical for DENV propagation and disease.
  • Understanding DENV entry mechanisms is key to developing antiviral therapies.

Purpose of the Study:

  • To review carbohydrate-derived molecules that inhibit DENV entry.
  • To explore compounds with similar mechanisms of action against DENV entry.

Main Methods:

  • Focus on the role of the DENV envelope (E) protein in receptor binding and membrane fusion.
  • Investigate the inhibitory effects of carbohydrate molecules like sulfated glycosaminoglycans (GAGs) and glycosphingolipids.
  • Examine the function of lectins (carbohydrate-recognition proteins) in blocking DENV entry.

Main Results:

  • Carbohydrate molecules and lectins demonstrate inhibitory effects on DENV entry.
  • The DENV E protein mediates virus-receptor binding and subsequent fusion within endosomes.
  • Specific carbohydrate structures and their interactions with viral proteins are crucial for inhibition.

Conclusions:

  • Carbohydrate-derived compounds represent a promising strategy for developing novel anti-dengue agents.
  • Targeting the DENV entry process offers a viable therapeutic approach.
  • Further research into these inhibitors could lead to effective dengue treatments.

More Related Videos

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction08:36

Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction

Published on: November 1, 2018

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.